Effect of Nilapalil Combined with Bevacizumab in the Treatment of Ad-vanced Ovarian Cancer and Its Effects on Peripheral Blood T Lymphocyte Subsets and Apoptosis Factors

ZHA Jingjuan; ZHENG Xiaoting; WU Shengbao

doi:10.3969/j.issn.1002-3429.2024.01.015

Abstract：Objective To explore the efficacy of Nilapalil combined with Bevacizumab in the treatment of advanced ovarian cancer.Methods A total of 80 patients with advanced ovarian cancer treated from September 2020 to September 2023 were selected and divided into observation group(n =40)and control group(n =40)by random number table method.The observation group was given Bevacizumab combined with Nilapalil on the basis of TP chemotherapy,and the control group was given Bevacizumab combined with TP chemotherapy for 4 cycles.The therapeutic effect of the two groups and serum canc-er antigen(CA)125,CA153,human epididymal protein 4(HE4),hypoxia-inducible factor-1α(HIF-1α),angiogenin-2(Ang-2),vascular endothelial growth factor(VEGF),B-cell lymphoma-2(Bcl-2),B-cell CLL/lymphoma-2-associated ath-anogene 1(BAG-1),CD3+,CD4+,and CD4+/CD8+before and after treatment as well as the incidence of toxic and side effects were compared in the two groups.Results The total effective rate was 90.00%(36/40)in the observation group and 72.50%(29/40)in the control group(P＜0.05).The levels of CA153,HE4,CA125,VEGF,Ang-2,HIF-1α,VEGF,Ang-2,and HIF-1α decreased gradually with the extension of treatment time.CD3+,CD4+,and CD4+/CD8+in the observation group first decreased and then stabilized with the extension of treatment time,while the control group showed a continuous decreasing trend(P＜0.05).After 2 and 4 cycles of treatment,CA153,HE4,CA125,VEGF,Ang-2,HIF-1α,Bag-1 and Bcl-2 in observation group were lower than those in control group,while CD3+,CD4+and CD4+/CD8+in ob-servation group were higher than those in control group(P＜0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P＞0.05).Conclusion Nilapalil combined with Bevacizumab can regulate the levels of apoptosis factors and angiogenesis factors in advanced ovarian cancer patients,alleviate immune damage,inhibit the level of tumor markers,and improve the therapeutic effect.